Try our Advanced Search for more refined results

Expert Analysis

Lot Of Inversion Talk, But Do You Know The Basics?

Law360, New York (August 7, 2014, 10:45 AM EDT) -- Much ink has been spilt recently on the topic of "inversion" transactions — from Pfizer's failed pursuit of AstraZeneca, to the $48 billion Medtronic/Covidien deal, to the more recent and creative Cosmo Technologies/Salix Pharmaceuticals and Mylan/Abbott transactions. Advocates of inversions claim the deals seek to create shareholder value; detractors condemn them as unpatriotic and immoral. This article does not take sides in the debate but rather clarifies the basic elements of these transactions, which are sometimes misunderstood....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!